Inspire's Q1 2026 print attributes a combined $120 to $150 million FY26 hit to WISeR plus coding uncertainty, six sell-side analysts cut targets through 7 May, and NeuroPace just received a 43% to 47% Medicare reimbursement increase on the same rule cycle.
Sydney and San Francisco-based Omniscient Neurotechnology closed a $27.2 million (AU$41.1 million) Series D funding round on 29 May 2026, co-led by OIF Ventures and the Australian National Reconstruction Fund Corporation. The capital scales the company's FDA-cleared Quicktome connectomics platform for neurosurgical planning, with the company explicitly naming brain-computer interface, stroke, and movement disorders as the next expansion indications. Omniscient is a connectomics company rather than a BCI implant company; the BCI angle is forward-looking adjacency rather than current product.
Rice University and Baylor College of Medicine announced on 28 May 2026 that they have joined the BrainGate research consortium, the multi-institutional clinical brain-computer interface network founded by John Donoghue at Brown University. The Texas team is the sixth in the consortium and the first based outside the eastern and western US clusters. The Rice-Baylor work focuses on decoding cortical neural signals to operate assistive robotic devices that help people with tetraplegia eat and drink independently. The expansion lands the same week Donoghue was named a 2026 Queen Elizabeth Prize for Engineering co-laureate for his BrainGate-anchored work.
Tencent Holdings has acquired a minority equity stake in Nanochap Electronics, a Hangzhou-based fabless semiconductor company specialising in neural interface and biosensing SoCs for brain-computer interface and medical device applications. The investment was disclosed through a 28 May 2026 business registration filing showing Shanghai Qishan Investment, a Tencent subsidiary, added as a new shareholder. Nanochap's registered capital increased to RMB 16.8853 million. Exact stake size and investment amount have not been publicly disclosed. The move follows the April 2026 StairMed funding round in which Alibaba led and Tencent joined, and signals a sustained pattern of Chinese big-tech equity participation in the country's BCI silicon supply chain.
Shanghai-based NeuroXess says a 35-year-old woman with epilepsy fitted with its 256-channel surface-cortex implant has been decoded reading Mandarin at 300 characters per minute through a large language model layer, faster than the roughly 220 cpm rate of a native Mandarin first-language speaker. Co-founder and chief scientist Tiger Tao disclosed the figure to Nature on 19 May 2026. The underlying paper has not yet been published, but the result sits on top of NeuroXess's already peer-reviewed Science Advances paper from 5 November 2025 (71.2% accuracy across 394 Mandarin syllables in a 43-year-old woman with epilepsy).
ONWARD Medical reported Q1 2026 results on 26 May 2026 with EUR 2.0 million in revenue (EUR 1.3 million ARC-EX systems across 100+ clinics, 70 systems supplied including first home-use shipments to US VA patients), two additional ARC-BCI participants bringing the total to seven, and first participant enrolled plus first implant in the Empower BP pivotal study at Craig Hospital, Denver. The company holds EUR 53.4 million in cash before adding over EUR 40 million from the April equity raise, extending runway into Q1 2028.
ABILITY Neurotech, the Geneva-based Wyss Center spinout building Europe's first fully implantable wireless optical-link ECoG brain-computer interface, received Investigational Medical Device Dossier (IMDD) approval from MREC NedMec in the Netherlands on 26 May 2026 to begin the first chronic implantation study of its device in ALS patients at UMC Utrecht under the INTRECOM consortium.
Belgian neurotech ReVision Implant closed an oversubscribed €4 million seed round in May 2026 to bring manufacturing of its Occular cortical vision prosthesis in-house ahead of a first-in-human trial cleared for Q3 2026 (October surgical-window cohort), with broader early-stage trials in blind volunteers expected in summer 2027. The round follows FDA Breakthrough Device Designation granted in March 2026.
Inspire Medical Systems reported Q1 2026 revenue of $204.6 million (up 1.6% year-on-year) on 4 May 2026 and cut full-year 2026 guidance to $825-875 million from the prior $950 million-$1 billion range issued in February. The company attributed approximately $20 million of Q1 impact to CMS WISeR prior authorization and CPT code transition uncertainty. Bank of America analyst Travis Steed downgraded the stock from Neutral to Underperform.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.